MedTrace Logo

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

NCT04153409 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-04-28

Study results available
· View outcomes & findings →

Summary

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

Conditions

  • Acute Migraine

Interventions

DRUG

LAT8881

Two 30 mg capsules of LAT8881

DRUG

Placebo

Two capsules of placebo

Sponsors & Collaborators

  • Lateral Pharma Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2020-02-15
Completion
2020-04-10
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04153409 on ClinicalTrials.gov